

Sheep polyclonal antibody to dephosphorylated Catenin beta (28-46): Affinity purified

Catalogue No.: S-1233-100

Description: Catenin beta is an adherens junction protein and has a role in the regulation of cell adhesion

and in signal transduction through the Wnt pathway. At least 2 isoforms are produced by

alternative splicing.

Batch No.: See product label

Unit size: 100 ug

Antigen: A synthetic peptide (C-QSYLDSGIHSGATTTAPSL) corresponding to the amino acid region

28-46 of human Catenin beta coupled to carrier protein KLH. This antibody was designed to detect the active form of Catenin beta. The antibody exhibits a strong preference for dephosphorylated beta catenin protein by western blot but the antibody may show cross

reactivity with phosphorylated catenin beta under certain conditions.

Other Names: Catenin beta-1; Beta-catenin; CTNNB1; CTNNB; _-Catenin;

Accession: P35222 CTNB1_HUMAN;

Produced in: Sheep

Purity: Affinity purified

Applications: Western Blotting (WB) and Immunocytochemistry. A concentration of 2.0 ug/mL is

recommended for WB. Human Catenin beta (isoform 1) has a predicted length of 781 residues and MW of 86 kDa. It has been observed as a 92 kDa band in SDS-reducing gels. A concentration of 4.0 ug/mL is recommended for Immunocytochemistry. Biosensis recommends

optimal dilutions/concentrations should be determined by the end user.

Specificity: The specificity of this antibody has been confirmed by WB against the antigen.

Cross-reactivity: Human; mouse; rat;


Form: Lyophilised from 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, and 0.05 % sodium azide.

Reconstitution: Reconstitute in 100 uL of sterile water. Centrifuge to remove any insoluble material.

Storage: At least 12 months after purchase at 2-8C (lyophilized formulations). After reconstitution,

aliquot and store at -20C for a higher stability. Avoid freeze-thaw cycles.

Expiry Date: 12 months after purchase



Western blot analysis of Catenin beta (S-1233-100) in extracts from HepG2 cells: untreated (Lane 1) and treated with GSK3 inhibitor (Lane 2).

FOR RESEARCH USE ONLY